Nasdaq
$2.01▲ 0.25%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $117.7MShares out 58.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
13- 10.5After-hours26.10.06 05:283Ownership#●●●#●●●
Foghorn Therapeutics Inc.
BVF Partners L.P. and its affiliated investment entities have filed a Form 3, disclosing their initial beneficial ownership of Foghorn Therapeutics Inc. securities. This filing confirms the entry of this investment group as a new significant shareholder in the company.…more
$2.01+0.25%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.5After-hours26.10.06 05:27SCHEDULE 13G/AOwnership
Foghorn Therapeutics Inc.
This is a SCHEDULE 13G/A filing regarding the beneficial ownership of Foghorn Therapeutics Inc. by Biotechnology Value Fund L.P. The investor has updated its filing to confirm its existing stake in the company.…more
$2.01+0.25%vs prev closeView filingShare - 10.1Pre-market26.10.01 20:018-KKey event
Foghorn Therapeutics Inc.
Foghorn Therapeutics has decided to discontinue the development of FHD-909 and terminate its partnership with Eli Lilly following Phase 1 clinical trial results. As part of a strategic reprioritization, the company is reducing its workforce by approximately 40%, incurring aggregate charges of approximately $2.3 million. These measures are intended to extend the company's cash runway into the second half of 2029 while focusing on proprietary pipeline programs.…more
$2.01+0.25%vs prev closeView filingShare
12 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.1Regular26.10.02 01:17Bullish#●●●#●●●#●●●
Foghorn Therapeutics Ends Eli Lilly Deal and Announces 40% Workforce Reduction…more
Foghorn Therapeutics is discontinuing its collaboration with Eli Lilly to focus on its wholly owned pipeline. The company also announced a 40% workforce reduction to extend its cash runway, sending shares to a 52-week low.…more
$2.01+0.25%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.1Pre-market26.10.01 20:25
●●●●●●●● ●●●●● ●●●●●●
Trading for a specific stock was temporarily halted and has since resumed. This is a standard procedure following market volatility or the release of specific news.…more
$2.01+0.25%vs prev closeShareBenzinga - 10.1Pre-market26.10.01 20:17
●●●●●●●● ●●●●● ●●●●●●
Foghorn Therapeutics and Lilly have decided not to advance the FHD-909 program into clinical expansion following Phase 1 trial results. The companies are ending their collaboration, and Foghorn will now prioritize its proprietary portfolio.…more
$2.01+0.25%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report